Quick Takeaways
- This page summarizes Wei Lin's Form 4 filing for Revolution Medicines, Inc. (RVMD).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 18 Jun 2025, 16:05.
Wei Lin - 16 Jun 2025 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)
- Signature
- /s/ Jack Anders, as Attorney-in-fact for Wei Lin
- Issuer symbol
- RVMD
- Transactions as of
- 16 Jun 2025
- Net transactions value
- -$86,551
- Form type
- 4
- Filing time
- 18 Jun 2025, 16:05:01 UTC
- Previous filing
- 15 May 2025
- Next filing
- 18 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Wei Lin filed Form 4 for Revolution Medicines, Inc. (RVMD) on 18 Jun 2025."
What Changed
- Previous filing in this sequence was filed on 15 May 2025.
- Current net transaction value: -$86,551.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Wei Lin | Chief Medical Officer | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY | /s/ Jack Anders, as Attorney-in-fact for Wei Lin | 18 Jun 2025 | 0001872772 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RVMD | Common Stock | Sale | $86,551 | -2,173 | -2.3% | $39.83 | 90,499 | 16 Jun 2025 | Direct | F1, F2, F3, F4 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025. |
| F2 | This transaction was executed in multiple trades in prices ranging from $39.6017 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| F3 | Includes 1,021 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025. |
| F4 | Includes 64,800 RSUs. |